Previous 10 |
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...
Gainers: PLAY +7.6% . OTCQB:HLIX +3.8% . EVC +2.8% . PTGX +2.3% . ODT +2.1% . More news on: Dave & Buster's Entertainment, Inc., Helix TCS, Inc., Entravision Communications Corporation, Stocks on the move, Read more ...
Reata Pharmaceuticals, Inc. (RETA) Q4 2018 Results Earnings Conference Call February 27, 2019 08:00 PM ET Company Participants Vinny Jindal - VP, Strategy Warren Huff - CEO Colin Meyer - CMO Jason Wilson - CFO Conference Call Participants Yigal Nochomovitz - Citigroup ...
Reata Pharmaceuticals (NASDAQ: RETA ): Q4 GAAP EPS of -$0.86 beats by $0.21 . More news on: Reata Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more ...
PIVOTAL TRIALS CARDINAL AND MOXIE FULLY ENROLLED WITH DATA EXPECTED SECOND HALF 2019 FALCON PIVOTAL PHASE 3 TRIAL TO INITIATE IN MID-2019 CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR TODAY, FEBRUARY 28, 2019 IRVING, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Reata Pharmace...
IRVING, Texas, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs on Thursday, February 28 th , 2...
Final results from a Phase 2 clinical trial, PHOENIX , evaluating Reata Pharmaceuticals' ( RETA +1.7% ) bardoxolone methyl in patients with rare types of chronic kidney disease (CKD) showed a treatment effect. The company first reported the positive outcome in September 2018. More ...
STATISTICALLY SIGNIFICANT IMPROVEMENT IN KIDNEY FUNCTION OBSERVED IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER 12 WEEKS OF TREATMENT BARDOXOLONE METHYL SIGNIFICANTLY IMPROVED KIDNEY FUNCTION IN PATIENTS FROM ALL FOUR COHORTS OF PHOENIX BARDOXOLONE METHYL SIGNIFI...
NEW YORK,, Feb. 05, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LPL Financial Holdings Inc. (NASDAQ:LPLA), The Andersons, Inc. (NASDAQ...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...